Innovation Signal 70 (2026) | 28 October 2026
Difficult neural tissues are becoming easier to edit directly inside the body
Short note, about 5 minutes to read.
What happened
Editing genes directly inside the body is not new. But some tissues, particularly in the nervous system, remain difficult to reach with enough editing machinery to produce a meaningful effect.
That is beginning to change.
Researchers led by the Broad Institute of MIT and Harvard and Harvard University developed a system that delivered base editors to the brains of mice carrying a human form of the protein involved in prion disease. The treatment reduced levels of the disease-causing protein and extended the animals’ lifespan by 52%.
Independently, researchers led by the Institute of Molecular and Clinical Ophthalmology Basel (IOB) developed a base-editing approach for a genetic disorder affecting the retina. In non-human primates, the system edited an average of 75% of cone cells and 87% of retinal pigment epithelial cells at the treated locations.
Together, the results show that genome-editing systems are becoming more capable of reaching and modifying cells in difficult neural tissues directly inside the body.
Why this matters
Many genetic diseases affect tissues that are difficult to reach and cannot simply be removed from the body, edited and returned.
That makes delivery one of the central challenges for treating conditions involving the brain, retina and other parts of the nervous system.
If genome-editing systems can increasingly reach these tissues and modify enough of the relevant cells, genetic medicine could become applicable to conditions that are difficult to address through approaches that depend on treating cells outside the body.
Who should care
- Genetic medicine and gene-editing companies
- Neuroscience and ophthalmology researchers
- Pharmaceutical and biotechnology companies
- Hospitals and specialist treatment centres
- Organisations developing therapies for inherited neurological and retinal diseases
- Investors tracking emerging genetic medicines
What could change over the next 2 to 3 years
The next important evidence will be whether genome-editing systems can reach difficult neural tissues more consistently while maintaining precise editing and limiting unwanted effects.
Watch for longer follow-up in animal studies, improvements in delivery and the first clinical studies testing whether these approaches can safely produce meaningful levels of editing in people.
What might block this
Reaching difficult neural tissues does not by itself make genome editing safe or effective.
The editing machinery must reach enough of the intended cells while limiting unwanted changes elsewhere. Effects must also persist without causing harmful immune responses or damaging sensitive tissue.
Most importantly, the recent results are preclinical. They do not yet show that these approaches can safely and effectively edit neural tissues in people.
Why I am sharing this
Genetic editing is only useful if the editing machinery can reach the cells that matter.
For difficult neural tissues, that delivery problem has sharply limited where genome editing can be applied inside the body. Recent research suggests that boundary is beginning to move.
The map of tissues that genetic medicine can potentially reach is starting to expand.
If you found this useful, please consider forwarding it to someone who may also find it valuable.
Archive Tags
Genome Editing · Genetic Medicine · Neural Tissues · Base Editing